FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL										
	OMB Number: 3235-0287										
Estimated average burden											
	hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

				1 1100		on 30(h) of the					, ,				
1. Name and Address of Reporting Person* BENZENO SHARON					Name and Tick ive Biotecl				(Ch	eck all applic	cable)	Person(s) to Iss 10% Ov Other (s	vner		
(Last) (First) (Middle) C/O ADAPTIVE BIOTECHNOLOGIES CORP. SUITE 200					3. Date o	of Earliest Trans	action (M	onth/E	Day/Year)		below)	below) below) Chief Business Development Off			
(Street) SEATTLE WA 98102 (City) (State) (Zip)						endment, Date c	f Original	Filed	(Month/Day	Line	e) <mark>X</mark> Form fi Form fi	lividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person			
		Tak	le I - Non-l	Deriva	ative Se	curities Ac	quired,	Dis	osed of	f, or Ben	eficiall	y Owned			
1. Title of Security (Instr. 3)		0	. Transa Date Month/D	ay/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	Transaction Code (Instr.		ies Acquired Of (D) (Instr		Securitie Beneficia Owned F	5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
							Code	v	Amount	(A) or (D)	Price	Transact (Instr. 3 a	tion(s)		(Instr. 4)
Common	Stock			05/19/	/2020		M ⁽¹⁾		60,000) A	\$1.98	3 60,	,000	D	
Common Stock				05/19/2020			M ⁽¹⁾		18,750) A	\$6.32	2 78,	,750	D	
Common Stock				05/19/2020			M ⁽¹⁾		15,416	15,416 A		7 94,	94,166		
Common Stock				05/19/2020			M ⁽¹⁾	M ⁽¹⁾		5 A	\$6.5	5 172	172,291		
Common Stock				05/19/2020			M ⁽¹⁾		49,479) A	\$6.5	5 221	.,770	D	
Common	Stock			05/19/	/2020		M ⁽¹⁾		25,000) A	\$7.2	7 246	5,770	D	
Common Stock 05/1			05/19/	/2020		S ⁽¹⁾		246,770 D		\$40		0			
						urities Acqı s, warrants						Owned			
1. Title of Derivative Conversion Date Execution I Security Or Exercise (Month/Day/Year) if any		3A. Deemed Execution Dat if any (Month/Day/Ye	C	ansaction ode (Instr.	5. Number of Derivative Securities Acquired	Expiration	6. Date Exercisable Expiration Date (Month/Day/Year)		of Securities		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned	Ownership Form:	11. Nature of Indirect Beneficial Ownership (Instr. 4)	

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		ansaction of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$1.98	05/19/2020		M ⁽¹⁾			60,000	(2)	04/13/2024	Common Stock	60,000	\$0.00	0	D	
Stock Option (Right to Buy)	\$6.32	05/19/2020		M ⁽¹⁾			18,750	(3)	09/16/2026	Common Stock	18,750	\$0.00	1,250	D	
Stock Option (Right to Buy)	\$6.27	05/19/2020		M ⁽¹⁾			15,416	(4)	04/25/2027	Common Stock	15,416	\$0.00	4,584	D	
Stock Option (Right to Buy)	\$6.55	05/19/2020		M ⁽¹⁾			78,125	(5)	02/07/2028	Common Stock	78,125	\$0.00	45,875	D	
Stock Option (Right to Buy)	\$6.55	05/19/2020		M ⁽¹⁾			49,479	(6)	10/01/2028	Common Stock	49,479	\$0.00	75,521	D	
Common Stock (Right to Buy)	\$7.27	05/19/2020		M ⁽¹⁾			25,000	(7)	02/07/2029	Common Stock	25,000	\$0.00	50,000	D	

Explanation of Responses:

- 1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020.
- 2. The option is vested and fully exercisable.
- 3. The options vested with respect to 1/4 of such shares on July 26, 2017, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
- 4. The options vested with respect to 1/4 of such shares on April 19, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
- 5. The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
- 6. The options vested with respect to 1/4 of such shares on October 1, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

7. The options vested with respect to 1/4 of such shares on January 1, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

Remarks:

/s/ Sharon Benzeno by Eric Billings, Attorney in Fact

05/21/2020

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.